What is the recommended management of Mycobacterium ulcerans infection (Buruli ulcer), including antibiotic regimen and wound care?

Buruli Ulcer (Mycobacterium ulcerans Infection)

Recommended Treatment Approach

For Buruli ulcer, surgical debridement combined with skin grafting remains the treatment of choice for large established ulcers, while rifampin plus streptomycin for 8 weeks is highly effective for early, limited lesions and can cure nearly half of all cases without surgery. 1, 2

---

Antibiotic Regimen

First-Line Treatment: Rifampin + Streptomycin

• Administer rifampin 10 mg/kg orally once daily plus streptomycin 15 mg/kg intramuscularly once daily for 8 weeks as the WHO-recommended standard regimen 2, 3
• This combination achieves 96% treatment success rates and prevents M. ulcerans growth in human tissue within 4 weeks 2, 4
• No patients discontinue therapy due to antibiotic side effects in large cohort studies 2
• Recurrence rates are extremely low at 1.44% one year after treatment completion 2

Alternative Regimen to Reduce Injectable Duration

• For patients unable to tolerate 8 weeks of intramuscular injections: rifampin 10 mg/kg plus streptomycin 15 mg/kg daily for 4 weeks, followed by rifampin 10 mg/kg plus clarithromycin 7.5 mg/kg orally twice daily for 4 weeks 3
• This modified regimen shows similar efficacy (91% vs 96% healing rates) while reducing injection burden 3
• Three vestibulotoxic events occurred across both regimens in clinical trials 3

Older Guideline Recommendations (Less Effective)

• Historical guidelines suggested clarithromycin plus rifampin for controlling ulcer complications, but acknowledged disappointing results for established ulcers 1
• Rifampin monotherapy was mentioned only for preulcerative lesions 1

---

Surgical Management

Indications for Surgery

• Large established ulcers (>15 cm diameter) require surgical debridement combined with skin grafting as primary treatment 1, 2
• 73% of patients with lesions >15 cm undergo surgery versus only 17% with lesions <5 cm 2

Antibiotic-Only Treatment Success

• 47% of all Buruli ulcer cases can be cured with antibiotics alone without surgical intervention 2
• Lesions <5 cm diameter are particularly amenable to antibiotic-only treatment, with most avoiding surgery entirely 2
• Preulcerative nodules and plaques can be treated effectively by excision and primary closure, or antibiotics alone 1

Combined Approach

• When surgery is performed, administer postsurgical antimycobacterial treatment to prevent relapse or metastatic infection 1
• 53% of successfully treated patients receive antibiotics plus surgical excision and skin grafting 2

---

Wound Care and Monitoring

Clinical Response During Treatment

• Lesions do not enlarge during antibiotic treatment; most become smaller 4
• After 4 weeks of rifampin-streptomycin, rapid onset of local cellular immune responses occurs with phagocytosis of extracellular M. ulcerans 5
• By 8 weeks, extensive chronic infiltrates form granulomas with intra- and extracellular bacterial debris 5

Heat Therapy Option

• Heat therapy can be used for preulcerative lesions as an alternative to antibiotics or excision 1

---

Key Clinical Pearls

Lesion Size as Decision Point

• Lesion diameter at treatment initiation is the major factor determining need for surgical intervention 2
• Use 5 cm and 15 cm as thresholds: <5 cm favors antibiotics alone, >15 cm typically requires surgery 2

Treatment Duration and Efficacy

• 4 weeks of rifampin-streptomycin inhibits M. ulcerans growth in human tissue, but 8 weeks is recommended for complete treatment 4
• Culture conversion from positive to negative occurs reliably after 4 weeks of treatment 4

Common Pitfalls to Avoid

• Do not rely solely on antibiotics for large established ulcers—surgical debridement is essential 1
• Most antimycobacterial agents used for other NTM infections are ineffective for Buruli ulcer 1
• The disease causes severe scarring and deformities of extremities if inadequately treated, particularly in children and young adults 1